Bedrock Therapeutics Inc Profile last edited on: 2/17/2023
CAGE: 82SX8
UEI: SB2ZXJBQ4SX3
Business Identifier: AAV R&D gene therapy 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
8628 Valley Brook Drive
Chapel Hill, NC 27613
Chapel Hill, NC 27613
| (919) 605-2122 |
| info@bedrocktherapeutics.com |
| www.bedrocktherapeutics.com |
Location: Single
Congr. District: 02
County: Orange
Congr. District: 02
County: Orange
Public Profile
Bedrock Therapeutics is an AAV research and development company working both on platform technologies and therapeutic cassettes for diverse genetic diseases. The firm is structured around development of a method to improve the success of human corneal transplants by controlling the human bodys immune response and reduce transplant rejection
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2024 | 2 | NIH | $1,225,387 | |
| Project Title: Prevention of Corneal Transplant Rejection Using Aav-Hla-G Combination Therapy | ||||
| 2022 | 1 | NIH | $261,080 | |
| Project Title: Rational design of AAV vectors with human hepatocyte tropism and neutralizing antibody evasion | ||||
| 2021 | 1 | NIH | $328,150 | |
| Project Title: Immunosuppressive Gene Therapy for Ocular Graft vs Host Disease | ||||
| 2020 | 1 | NIH | $249,310 | |
| Project Title: Develop humanized AAV vectors for liver targeting and neutralizing antibody evasion | ||||
Key People / Management
Matthew Hirsch -- President and Co-Founder, Director of AAV Ocular Therapy
Brian C Gilger -- Co-Founder, Director of Preclinical Evaluation and Toxicology
Sun Junjet Al
Chengwen Li
Fran Martin -- Vice President, Commercial Development and Consulting
Junjiang Sun
Roger �bryan� Sutton
Brian C Gilger -- Co-Founder, Director of Preclinical Evaluation and Toxicology
Sun Junjet Al
Chengwen Li
Fran Martin -- Vice President, Commercial Development and Consulting
Junjiang Sun
Roger �bryan� Sutton
Company News
There are no news available.
